Rezolute (RZLT) announced the DMC’s recommendation to continue the Phase 3 sunRIZE study as planned in patients with congenital HI, without an increase in the study sample size. The interim analysis ...
The independent DMC (Data Monitoring Committee) of the COVA study recommends to continue patients recruitment into Part 2 of the phase 2-3 study following randomization of the first 155 patients Top ...
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (the “Company or “Rezolute”), a late-stage biopharmaceutical company dedicated to developing transformative ...
Soligenix, Inc, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, has received a positive ...
Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from the Data Monitoring Committee (DMC) to continue. The DMC's decision comes ...
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback